Home > Insider Trading > Filing (0001171843-15-000934)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
3116	Akorn Inc	AKRX	Pharmaceutical Preparations (2834)	720717400

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1234712	Joseph Bonaccorsi	1925 West Field Court Suite 300 Lake Forest IL 60045	Secretary	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2015-02-18	7,500	$1.46	319,189	No	4	M	Direct
Common Stock	Acquisiton	2015-02-18	92,500	$1.46	411,689	No	4	M	Direct
Common Stock	Disposition	2015-02-18	40,827	$47.33	370,862	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2015-02-18	7,500	$0.00	7,500	$1.46
Common Stock	Stock Option (right to buy)	Disposition	2015-02-18	92,500	$0.00	92,500	$1.46

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
92,500		2015-02-22	No	4	M	Direct
0		2015-02-22	No	4	M	Direct

Footnotes

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 21, 2014.
Upon execution of transactions disclosed on this Form 4, all securities subject to the 10b5-1 trading plan have been transacted and the plan has expired pursuant to its terms.
All proceeds from the sale were used to cover exercise price and taxes due upon exercise of options.
Reflects the weighted average sale price of the shares sold. The shares were sold in multiple trades at prices ranging from $46.80 to $48.49 per share. The reporting person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at separate prices within the foregoing range.
Amount of Shares Beneficially Owned Following Reported Transaction includes 104,414 unvested shares subject to a restricted stock awards and 266,448 shares owned outright. Shares owned outright include 1,015 shares acquired through participation in the Employee Stock Purchase Plan for the 2014 plan year.
The option vested in three annual installments with 33,333 options vesting on each of February 22, 2011 and February 22, 2012, and 33,334 options vesting on February 22, 2013.
Exercise of stock options that were approaching their 5-year expiration date.
There was no consideration given in exchange for the security.